ALEXANDRIA, Va., July 9 -- United States Patent no. 12,351,559, issued on July 8, was assigned to Biohaven Therapeutics Ltd. (Tortola, British Virgin Islands).
"Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators" was invented by Lynn Resnick (Pittsburgh), George T. Topalov (Pittsburgh), Justin K. Belardi (Pittsburgh), James S. Hale (Pittsburgh), Scott S. Harried (Pittsburgh), Charles A. Flentge (Mars, Pa.) and David A. Mareska (McMurray, Pa.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, an...